A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
Lead Research Organisation:
University College London
Department Name: Medicine
Abstract
There is a need for new therapies to reduce time to remission in patients suffering from ANCA associated Vasculitis treated with Rituximab. This projects mechanistically investigates the utility of targeting the Bcell survival factor B-Lys in combination with rituximab in reducing remission in the setting f ANCA associated Vasculitis
Technical Summary
Experimental medicine study to investigate the combination of belimumab and rituximab in man
Organisations
People |
ORCID iD |
| Alan Salama (Principal Investigator) | |
| Paul Brogan (Co-Investigator) |
Publications
Sonnemann J
(2019)
050. URINARY REGULATORY T-LYMPHOCYTES IDENTIFY ACTIVE RENAL ANCA-ASSOCIATED VASCULITIS
in Rheumatology
| Title | urinary lymphocyte analysis |
| Description | we have optimised the urinary lymphocyte assay in ANCA associated vasculitis which has enabled us to define renal disease activity and identify more subtle renal involvement even when conventional biomarkers are not suggestive of renal disease activity. We have refined this method to enable us to collect fixed urine allowing a delay between collection and analysis. this is to be presented as new work at the ANCA workshop in April 2019 ( see publications) |
| Type Of Material | Biological samples |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | we are presenting these novel data and using the technique in the study |